Literature DB >> 29268459

Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy.

Donovan Watza1,2, Kristen S Purrington1,2, Kang Chen1,2,3, Ann G Schwartz1,2.   

Abstract

Entities:  

Year:  2017        PMID: 29268459      PMCID: PMC5721072          DOI: 10.21037/jtd.2017.10.35

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.

Authors:  Fayçal Djenidi; Julien Adam; Aïcha Goubar; Aurélie Durgeau; Guillaume Meurice; Vincent de Montpréville; Pierre Validire; Benjamin Besse; Fathia Mami-Chouaib
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

2.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

3.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.

Authors:  Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier
Journal:  Nat Immunol       Date:  2017-06-19       Impact factor: 25.606

4.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

5.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

6.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

9.  Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.

Authors:  Jaemoon Koh; Sehui Kim; Moon-Young Kim; Heounjeong Go; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Oncotarget       Date:  2017-02-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.